CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Enoxaparin 40 Mg/0.4 mL Injectable SolutionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)

Name (Synonyms) Correlation
drug2594 Unfractionated Heparin IV Wiki 0.71
drug2596 Unfractionated heparin SC Wiki 0.71
drug1199 Information leaflet Wiki 0.71
drug853 Enoxaparin 1 mg/kg Wiki 0.71
drug2673 WALC-R Wiki 0.71
drug588 Clopidogrel Wiki 0.50
drug852 Enoxaparin Wiki 0.24

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D054556 Venous Thromboembolism NIH 0.27
D060825 Cognitive Dysfunction NIH 0.25
D013923 Thromboembolism NIH 0.19
D013927 Thrombosis NIH 0.16

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0001268 Mental deterioration HPO 0.25
HP:0001907 Thromboembolism HPO 0.17

There are 2 clinical trials

Clinical Trials

1 A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients

This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.

NCT04409834 COVID-19 Venous Thromboembolism Arterial Thrombosis Drug: Unfractionated Heparin IV Drug: Enoxaparin 1 mg/kg Drug: Clopidogrel Drug: Unfractionated heparin SC Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
MeSH:Thrombosis Thromboembolism Venous Thromboembolism
HPO:Thromboembolism

Primary Outcomes

Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVT

Measure: Primary endpoint: Venous or arterial thrombotic events

Time: 28 days or until hospital discharge, whichever earlier

Secondary Outcomes

Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia

Measure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events

Time: 28 days or until hospital discharge, whichever earlier

2 Intermediate Dose Enoxaparin in Hospitalized Patients With Moderate-severe COVID19: A Pilot Phase II Single-arm Study, INHIXACOVID19

General objective of the study To assess the efficacy and safety of enoxaparin in hospitalized patients with moderate to severe COVID-19 (Coronavirus Disease 2019) infection. Study Design The study consists of two parts: - a phase II single-arm interventional prospective study including all patients treated with the study drug; - an observational prospective cohort study including all patients screened for receiving the study drug but not included in the phase II study. Patients will be enrolled from "date of study approval" for 1 month. Each patient will be followed-up for a minimum of 90 days after COVID19 diagnosis.

NCT04427098 COVID-19 Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution Drug: Enoxaparin

Primary Outcomes

Description: Rates of hospitalized patients dead for all-cause within 30 days and 90 days from the first LMWH subcutaneous injection

Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

Time: 30 days and 90 days from the first LMWH subcutaneous injection

Description: Based on the four levels scale of severity of symptoms. Any change from one level to another will be detected for all the enrolled patients, in order to evalutate the clinical efficacy of enoxaparin on the outcome of COVID 19.

Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

Time: This evaluation will be performed at 30 days and 90 days from the first LMWH subcutaneous injection

Description: Evolution of the clinical severity during treatment, based on the number and rate of patients admitted to ICU and the length of their ICU stay

Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

Time: This evaluation will be performed at 14 days (the last day of treatment adminstration), at 30 days and 90 days from the first LMWH subcutaneous injection

Description: Difference between groups in number of days of hospitalization from admission to discharge

Measure: To investigate the efficacy of enoxaparin in improving the clinical outcome of hospitalized patients with moderate-severe COVID-19.

Time: This evaluation will be performed at 90 days from admission

Secondary Outcomes

Description: Rate of adverse events (AEs) during treatment, at the end of treatment (EOT) and at 30 days after EOT. • Severity of AEs classified according to common terminology criteria for adverse events (CTCAE). The worst degree ever suffered will be considered.

Measure: To analyse the safety of enoxaparin in hospitalized patients with moderatesevere COVID-19.

Time: 45 days

Description: Occurrence of thromboembolic event at 90 days after COVID-19 diagnosis. Description of the type, distribution and severity of thromboembolic events.

Measure: To describe the rates and the types of thromboembolic events among hospitalized patients with confirmed diagnosis of COVID-19.

Time: 90 days

Related HPO nodes (Using clinical trials)

HP:0001907: Thromboembolism
Genes 27
HABP2 INHBA KCNN4 CYTB KIF20A MTRR CBS F2 FCGR2C SERPINC1 TNNT2 MTHFR KCNQ1 SLC4A1 PRDX1 TNNI3 MYPN ADA2 MMACHC PRKAR1A FLNC F13A1 PIEZO1 JAK2 PIGA EPOR HRG
Protein Mutations 3
G20210A G21210A R506Q
SNP 7
rs10276036 rs1128503 rs1202167 rs1202168 rs1202169 rs2235046 rs4148738